Quest sees registration of dengue test kit in Brazil; Tribogenics closes $2.5M in funding;

> Quest Diagnostics ($DGX) reports that the Simplexa dengue molecular test kit developed by its Focus Diagnostics products business has been registered for distribution in Brazil. Quest release

> Tribogenics closes $2.5 million in funding from a network of global angel investors and Flywheel Ventures. The funds will be used to commercialize new technology that enables miniature low-cost X-ray sources for a wide range of applications, including scientific instruments, security screening and medical devices. Tribogenics release

> In-vitro specialist Protagen and Bayer HealthCare Pharmaceuticals announce a new collaboration project for the clinical validation of diagnostic biomarkers in endometriosis. Protagen release

> Bangalore's S3V Vascular Technologies is establishing a facility to manufacture and develop products in intervention cardiology, neurology, peripheral and endovascular treatments. Item

> Amp Orthopedics announces the start of a clinical trial in adults with mild-to-moderate knee osteoarthritis to determine the safety and effectiveness of the company's nonthermal pulsed radio frequency technology to alleviate pain. Amp release

> Breast cancer patients who undergo targeted radiation are almost twice as likely to need a mastectomy later as those who get a full course of the treatment, according to study data. Report

And Finally... Olympus introduces a new microscope designed to deliver vivid 3-D images of structures 8mm deep. Item

Suggested Articles

Philips has launched a compact, single-use device for physically clearing potentially dangerous blood clots lodged in the arms and legs.

CapsoVision has received word from the FDA that they may offer the home use of their ingestible camera pill for scanning the small intestine.

Spinal Elements, maker of a wide range of implants and products for minimally invasive spine procedures, has filed a $100 million IPO.